Introduction {#jve1-sec-0005}
============

The major obstacle to HIV-1 eradication is a viral reservoir of latently infected cells that persists despite long-term antiretroviral therapy (ART) and causes a rebound of viraemia if treatment is interrupted [@jve1-bib-0001]. This persistent HIV-1 reservoir predominantly comprises a pool of resting memory CD4+ T cells that carry stably integrated, replication competent proviruses and, for the most part, do not produce virus particles [@jve1-bib-0002]. As major efforts are underway to develop novel therapeutic approaches aimed at reducing or eliminating the HIV-1 latent reservoir, accurate measurement of this reservoir has become a key priority in contemporary AIDS research.

SIV infection of non-human primates, such as rhesus macaques (RMs), has been utilised for over two decades as an *in vivo* model for studies of HIV-1 pathogenesis, prevention, and treatment [@jve1-bib-0006]. More recently, the RM model of SIV or SHIV infection has been developed and validated for studies of HIV-1 cure as a result of the availability of antiretroviral regimens that suppress plasma viraemia to levels comparable to those in HIV-1-infected patients on ART [@jve1-bib-0011]. As such, this animal model enables *in vivo* evaluation of novel therapeutic strategies that may involve high risk and/or combination interventions that would be difficult to directly test in HIV-1-infected humans. In addition, the SIV/RM model allows for more extensive tissue sampling, including tissues obtained through elective necropsy, thus enabling a more comprehensive anatomical and histological characterisation of the persistent SIV/SHIV reservoir *in vivo*. For these reasons, the development of assays that accurately measure the latent reservoir (LR) in this non-human primate model of HIV-1 infection is a high priority for HIV/SIV cure research.

Assays to quantify HIV/SIV reservoirs are rapidly evolving. There is currently great interest in identifying simple methods that do not rely on high cell frequencies and complex experimental systems to measure virus persistence and the impact of candidate cure strategies on virus reservoirs. In this setting, a repetitive-sampling *Alu-gag* PCR assay has been used widely to measure integrated HIV-1 DNA levels. This assay quantifies integrated proviral reservoir including both replication-competent and replication-defective viruses, in HIV-1-infected individuals on ART [@jve1-bib-0016]. The current gold standard for measuring replication-competent virus in resting CD4+ T cells from ART-treated, HIV-1-infected patients is the quantitative viral outgrowth assay (or QVOA) [@jve1-bib-0020], but this approach requires a large number of cells and is time- and resource-consuming. Results of the integrated HIV-1 DNA assay were strongly positively correlated with those of the QVOA [@jve1-bib-0022], meaning that, while an overestimate, integrated HIV-1 DNA may be helpful as a surrogate measure of virus persistence, particularly when cell numbers available for study are limited. The *Alu-gag* PCR assay measures integrated HIV-1 DNA by performing a nested PCR, in which the first PCR uses an HIV-1 primer in combination with a specific primer for*Alu,* the most abundant human short repeat element; and a second PCR that quantifies the provirus. This report describes the development and characterisation of a similar method to quantify integrated SIV-DNA in SIV/SHIV-infected RMs. We used this assay to quantify integrated SIV-DNA levels in 10 RMs during the acute and chronic phases of infection to establish a baseline level. We also quantified total and integrated SIV-DNA in CD4+ T cells from peripheral blood and lymphoid cells from 13 ART-treated RMs and found that these viral forms were positively correlated at each site and that the on-ART total and integrated SIV-DNA levels were not significantly different.

Methods {#jve1-sec-0006}
=======

Animals and samples {#jve1-sec-0007}
-------------------

We used samples from 10 SHIV-infected untreated Indian rhesus macaques (*Macaca mulatta*) involved in an ineffective vaccine study (unpublished). All macaques were challenged intrarectally with at least one dose of 10,000 TCID~50~ SHIVSF162p3. PBMC and plasma samples were collected at regular time points and frozen in liquid nitrogen and at −80°C. Two time points were analysed in this study, one during the early phase of infection (day 10 to 21) and one during the chronic phase of infection (day 126 to 364). We also obtained PBMC and lymphoid tissues from RMs involved in different ART studies. The animals and their treatments are summarised in Table [1](#jve1-tbl-0001){ref-type="table"}. Cells were isolated from lymphoid tissues [@jve1-bib-0023] and frozen in liquid nitrogen until use.

  Animals   Duration of infection (days)   Sample           Virus         Duration on ART (days)   Viral load (RNA copies/mL)   ART regimen
  --------- ------------------------------ ---------------- ------------- ------------------------ ---------------------------- ------------------------
  RM1       10                             PBMC             SHIVSF162p3   n/a                      3.80E+05                     n/a
  126       PBMC                           SHIVSF162p3      n/a           2.11E+05                 n/a                          
  RM2       14                             PBMC             SHIVSF162p3   n/a                      3.78E+05                     n/a
  84        PBMC                           SHIVSF162p3      n/a           7.80E+04                 n/a                          
  RM3       14                             PBMC             SHIVSF162p3   n/a                      9.20E+07                     n/a
  364       PBMC                           SHIVSF162p3      n/a           6.21E+05                 n/a                          
  RM4       14                             PBMC             SHIVSF162p3   n/a                      3.76E+07                     n/a
  84        PBMC                           SHIVSF162p3      n/a           1.83E+05                 n/a                          
  RM5       21                             PBMC             SHIVSF162p3   n/a                      1.54E+06                     n/a
  84        PBMC                           SHIVSF162p3      n/a           4.41E+02                 n/a                          
  RM6       14                             PBMC             SHIVSF162p3   n/a                      4.85E+06                     n/a
  126       PBMC                           SHIVSF162p3      n/a           9.47E+05                 n/a                          
  RM7       14                             PBMC             SHIVSF162p3   n/a                      1.63E+06                     n/a
  84        PBMC                           SHIVSF162p3      n/a           5.20E+03                 n/a                          
  RM8       14                             PBMC             SHIVSF162p3   n/a                      5.37E+06                     n/a
  126       PBMC                           SHIVSF162p3      n/a           1.37E+05                 n/a                          
  RM9       14                             PBMC             SHIVSF162p3   n/a                      1.55E+06                     n/a
  210       PBMC                           SHIVSF162p3      n/a           2.99E+05                 n/a                          
  RM10      14                             PBMC             SHIVSF162p3   n/a                      6.62E+05                     n/a
  308       PBMC                           SHIVSF162p3      n/a           1.00E+02                 n/a                          
  RM13      473                            ileac LN         SIVmac251     421                      \<60                         PMPA-FTC-RAL-DRV/r-MVC
  RM14      456                            ileac LN         SIVmac251     404                      \<60                         PMPA-FTC-RAL-DRV/r-MVC
  456       colonic LN                     SIVmac251        404           \<60                     PMPA-FTC-RAL-DRV/r-MVC       
  RM15      477                            ileac lLN        SIVmac251     425                      \<60                         PMPA-FTC-RAL-DRV/r-MVC
  477       colonic LN                     SIVmac251        425           \<60                     PMPA-FTC-RAL-DRV/r-MVC       
  RM16      241                            superficial LN   SIVmac251     183                      \<60                         PMPA-FTC-RAL-DRV/r
  241       spleen                         SIVmac251        183           \<60                     PMPA-FTC-RAL-DRV/r           
  RM17      261                            mesenteric LN    SIVmac251     203                      \<60                         PMPA-FTC-RAL-DRV/r
  261       spleen                         SIVmac251        203           \<60                     PMPA-FTC-RAL-DRV/r           
  RM18      210                            PBMC             SIVmac251     144                      \<60                         PMPA-FTC-ZDV-LPV/r
  RM19      210                            PBMC             SIVmac251     144                      \<60                         PMPA-FTC-ZDV-LPV/r
  RM20      210                            PBMC             SIVmac251     144                      7.59E+02                     PMPA-FTC-ZDV-LPV/r
  RM21      210                            PBMC             SIVmac251     140                      \<60                         PMPA-FTC-ZDV-LPV/r
  RM22      210                            PBMC             SIVmac251     140                      1.07E+02                     PMPA-FTC-ZDV-LPV/r
  RM23      210                            PBMC             SIVmac251     144                      \<60                         PMPA-FTC-ZDV-LPV/r
  RM24      210                            PBMC             SIVmac251     140                      \<60                         PMPA-FTC-ZDV-LPV/r
  RM25      210                            PBMC             SIVmac251     144                      \<60                         PMPA-FTC-ZDV-LPV/r

PMPA: tenofovir; FTC: emtricitabine; RAL: raltegravir; DRV/r: darunavir/ritonavir; MVC: maraviroc; LPV/r: lopinavir/ritonavir; ZDV: zidovudine.

Plasma SIV RNA quantification {#jve1-sec-0008}
-----------------------------

Plasma viral quantification was performed by RT-PCR as described previously [@jve1-bib-0024].

Preparation of a polyclonal integration standard {#jve1-sec-0009}
------------------------------------------------

The strategy used to prepare the polyclonal integration standard was previous described in detail [@jve1-bib-0016]. 293T cells were transfected with pSIVmac239Δenv-hygromycin-GFP and pVSV-G plasmids using standard CaPO~4~ transfection protocol. Supernatants were harvested 48 hours after transfection. RM B-LCL (B lymphoblastoid cells) were infected with the viral supernatant by spinoculation. The cells were infected at a low multiplicity of infection to minimise the chance of multiple transductions within one cell. Briefly, 16×10^6^ B-LCL were mixed with 1 mL of viral stock (VSV-G pseudotyped SIVmac239Δenv-hygromycin-GFP) diluted 1:4 in 10% FBS-RPMI 1640 medium and placed into one well of a flat-bottom six-well tissue culture plate. The plates were centrifuged at 1200*g* for 2 hours at 25^o^C. Cells were then maintained in culture for 1 week at 2×10^6^cells/mL. After hygromycin selection, transduced B-LCL were sorted for GFP expression. Sorted cells were cultured for a further 3 weeks and were again sorted for expression of GFP before DNA extraction. We measured the level of SIV-DNA per cell using quantitative PCR and found ∼1 copy of SIV per cell.

DNA extraction {#jve1-sec-0010}
--------------

Genomic DNA was extracted from B-LCL, PBMC or lymphoid tissue cells using the Qiagen Blood and cell culture maxi, midi or mini kit following the manufacturer instructions.

Cell number estimation {#jve1-sec-0011}
----------------------

The concentrations of RM genomes in the isolated sample DNA were determined by measuring the number of albumin copies by quantitative real-time PCR assay using Invitrogen Platinum *Taq* DNA polymerase. Two dilutions of the DNA samples were amplified in duplicate wells of a 96-well plate. A standard curve was made using purified DNA from uninfected RM PBMC. The sequences of the primers and probe used were: Forward primer: 5′-TGC ATG AGA AAA CGC CAG TAA-3′; Reverse primer: 5′-ATG GTC GCC TGT TCA CCA A-3′; probe 5′-6-FAM-AGA AAG TCA CCA AAT GCT GCA CGG AAT C-36-TAMSp.

Amplification of integrated SIV-DNA {#jve1-sec-0012}
-----------------------------------

The amount of integrated SIV-DNA was quantified using a repetitive sampling two-step PCR assay adapted from the method of O'Doherty *et al*. [@jve1-bib-0019]. The first amplification, targeting a region between SIV*gag* and the nearest *Alu* sequence, was performed in 42 replicates on 10,000 cell equivalent per reaction. Simultaneously, 42 replicates of gag-only primer amplification reactions were performed as a control to account for background signals from unintegrated SIV-DNA. The sequences of the first step amplification primers were: Alu Forward: 5′-TCT GCG TCA TCT GGT GCA TTC ACG-3′ and gag Reverse: 5′-TGC CAA CAG GCT CAG AAA ATT-3′. The reactions were carried out in 50 μL containing 1.5 mM MgCl~2~, 0.21 mM of mixed dNTPs, 100 nM Alu Forward primer and/or 600 nM gag Reverse primer and 5 U/reaction of Platinum *Taq* DNA polymerase. The thermal cycler was programmed to performed a 2-min hot start at 95^o^C, followed by 20 cycles of denaturation at 95^o^C for 15s, annealing at 50^o^C for 15s and extension at 72^o^C for 3 min and 30s.

The second-round real-time PCR specific for the SIV LTR was performed using 10 μL of the pre-amplification product diluted 1/8. The sequence of the primers and probes were: Forward 5′-ACG GCT GAG TGA AGG CAG TAA-3′, Reverse 5′-GAC CCG CGC CTT TAT AGG A-3′, Probe: 5′-FAM-CGG CAG GAA CCA ACC ACG ACG-3′-TAMRA. Reactions were carried out in a volume of 20 μL containing 5.5 mM MgCl~2~, 0.3 mM of mixed dNTPs, 260 nM of primers, 200 nM of probe and 2U of Platinum *Taq* DNA polymerase. The reactions were performed on a 7500 fast real-time PCR system (Applied Biosystems) with the following thermal program: 20-s hot start at 95^o^C, followed by 50 cycles of denaturation at 95^o^C for 3 s and annealing at 59^o^C for 30 s.

Analysis of integration levels {#jve1-sec-0013}
------------------------------

To generate the standard curve, the integration standard was diluted in PBMC DNA from SIV-negative RMs to obtain samples containing known numbers of integrated SIV-DNA. Dilutions ranging from 1 provirus to 100 proviruses diluted in 10,000 genomes equivalent per reaction were assessed using the two-step PCR assay described above. A student\'s *t*-test with a 95% confidence interval was performed to determine if cycle thresholds (Ct) derived from the *Alu-gag* PCR were significantly lower than those from the *gag*-only reactions (*P*\<0.1). A standard curve was then generated by plotting the natural log of the average Ct versus the natural log of the number of SIV-DNA copies in order to calculate a regression equation. This standard curve was used to determine the level of integrated SIV-DNA in RM samples based on the average Ct value of the *Alu-gag* reactions.

Total SIV-DNA quantification {#jve1-sec-0014}
----------------------------

PCR amplifications targeting the LTR region of SIV were performed using the same primers and probe used in the second step of the integration reaction in a single round of 50 cycles. DNA samples were diluted to contain 40,000 cells per well for analysis in triplicate wells of a 96-well plate. Ct values were inserted into a regression line equation obtained from a standard curve from the same reaction using dilutions with known copy numbers of a SIVmac239 full-length plasmid.

Statistical analyses {#jve1-sec-0015}
--------------------

Quantitative variables were compared using parametric *t*-tests. Correlations between quantitative variables were estimated by calculating Pearson\'s rank correlation coefficient. All tests were two-tailed and statistical significance was set at *P*\<0.05. Analyses were performed using GraphPad Prism v4.0.

Results {#jve1-sec-0016}
=======

Generation of a standard curve using an integrated SIV-DNA standard {#jve1-sec-0017}
-------------------------------------------------------------------

To quantify integrated SIV-DNA levels, peripheral blood mononuclear cells (PBMC) from SIV-infected RMs with unknown levels of SIV integration were compared to a standard containing diverse integration sites to accurately reflect the diversity of integration sites that occur *in vivo*. A polyclonal integration standard cell line (IS) containing one integration event per cell (not shown) was generated using a strategy similar to that previously described for HIV-1 and detailed here in the Methods. To measure SIV integration events, we used an *Alu*-PCR assay adapted from the method of O'Doherty and colleagues involving two amplifications and repetitive sampling [@jve1-bib-0016]. The first amplification step targets integrated SIV-DNA specifically by amplifying the region between SIV*gag* and the nearest *Alu* repeat element of the simian genome. *Alu-gag* signals are compared to the signals generated using only the *gag* primer, which approximates the signal expected from unintegrated DNA (Figure [1A](#jve-2-219-g001){ref-type="fig"}). Forty-two replicates of each reaction were assessed to increase the sensitivity of the assay and to compensate for integration specific bias (related to the variable distance between each unique integration site and *Alu* element) [@jve1-bib-0016]. The nested real-time PCR amplification recognises the R-U5 region of the SIV long terminal repeat. To generate a standard curve, the IS was serially diluted in DNA extracted from uninfected PBMC at 10,000 cell equivalent per reaction in order to obtain samples containing known numbers of integrated SIV-DNA copies. The two-step PCR assay described above was performed for each dilution and detected 1 provirus in 10,000 cells (10% of the time), very similar to the previously described assay [@jve1-bib-0016]. In our hands, the sensitivity of the assay depends on the number of genomes assayed. We robustly detect 1 provirus in 10,000 cells by assaying 10,000 cells per well x 42 wells as shown in Figure [1](#jve-2-219-g001){ref-type="fig"}. As previously reported, a linear relationship was observed between the natural logarithm of the average *Alu-gag* cycle threshold (Ct) and the natural logarithm of the proviral number: Ln (provirus)=−6.0835 Ln (Ct)+23.471 with r^2^=0.96756 (Figure [1B](#jve-2-219-g001){ref-type="fig"}), with 1 to 100 proviruses in 10,000 cell equivalents included in the linear range.

![Integration standard curve. The polyclonal integration standard DNA was diluted in uninfected PBMC DNA to a constant amount of 10,000 cell equivalents per reaction. Seven dilutions ranging from 1 to 100 copies per reaction were subjected to our two-step Alu-PCR. (A) The first PCR reaction used primers targeting *Alu* and *gag* or only primers to *gag*. The nested PCR reaction used SIV-specific primers binding to the LTR elements, R and U5. For each dilution sample, *Alu-gag* and *gag*-only (background) amplification was measured 42 times. At low proviral copy number, integration is detected at a low frequency as demonstrated by the *Alu-gag* amplification. For clarity, we did not show the *gag*-only signals at the lower dilutions, but instead show the bracketed black lines (\|---\|), which represent where the *gag*-only signal (background) was detected at each proviral number. (B) The natural log (Ln) of integrated SIV-DNA copy number is plotted on the y-axis against the Ln of the cycle threshold (Ct) of *Alu-gag* amplification on the x-axis. Each point represents the average Ln(Ct) for 42 replicates and the error bars represent the standard deviation. (C) SIV integration measurements were performed in six independent experiments on PBMC samples from three untreated RM to calculate the inter-assay coefficient of variation of the assay. Horizontal bars show means and standard deviations](jve-2-219-g001){#jve-2-219-g001}

Using PBMC samples obtained from three SIV-infected RMs, we determined the reproducibility of the integration assay. We measured the level of integrated SIV-DNA with six independent experiments performed for each of the three RMs (a total of \>250 wells per sample). Using untreated RM PBMC samples, the inter-assay coefficient of variation of the SIV *Alu-gag* integration assay was 0.057 (Figure [1C](#jve-2-219-g001){ref-type="fig"}), confirming its robustness. These results show that the basic principles of the HIV-*Alu* nested PCR assay to detect HIV-1 integration can be successfully applied to quantify the levels of SIV integration in RM samples.

Excess of unintegrated SIV-DNA is present in SHIV-infected RMs in the absence of ART {#jve1-sec-0018}
------------------------------------------------------------------------------------

The level of integrated SIV-DNA was determined in the PBMC of 10 SHIV-infected ART-naïve RMs and compared to the level of total SIV-DNA in the same samples (as measured by SIV*gag* RT-PCR) [@jve1-bib-0024]. PBMC were collected from the same animals during the acute and chronic stages of SHIV infection. Table [1](#jve1-tbl-0001){ref-type="table"} shows the characteristics of RMs used in this study. Integrated SIV-DNA was detected in 10/10 RMs during the acute phase of infection (Figure [2A](#jve-2-219-g002){ref-type="fig"}) and in 9/10 RMs during the chronic phase of infection (Figure [2B](#jve-2-219-g002){ref-type="fig"}). Of note, the RM for whom integrated SIV-DNA was below the limit of detection was a natural SHIV controller by week 8 post-infection and maintained plasma viral load under 200 copies/mL throughout the study in the absence of ART. Interestingly, the level of integrated SIV-DNA was approximately one log lower than the level of total SIV-DNA; with a median of 1660 copies of integrated SIV-DNA versus 22,500 copies of total SIV-DNA per million PBMC during the acute phase of infection (*P*=0.03; Figure [2C](#jve-2-219-g002){ref-type="fig"}) and a median of 866 copies of integrated SIV-DNA versus 8580 copies of total SIV-DNA per million PBMC during the chronic phase of infection (*P*=0.01; Figure [2D](#jve-2-219-g002){ref-type="fig"}). These results suggest an excess of unintegrated SIV-DNA (i.e. 49--96% of the total cell-associated SIV-DNA) as compared to integrated SIV-DNA for all RMs in the absence of ART, as previously reported for HIV-1-infected patients [@jve1-bib-0025]. The level of SIV-DNA in CD4+ T cells was also estimated based on the frequency of CD4+ T cells in PBMC determined by flow cytometry and the frequency of infection determined by PCR. The estimated level of integrated SIV-DNA in CD4+ T cells was approximately one log lower than the level of total SIV-DNA during the acute phase of infection; with a median of 15,300 copies of integrated SIV-DNA versus 161,500 copies of total SIV-DNA per million CD4+ T cells (*P*=0.04; data not shown). When normalised to CD4+ T cell frequencies, the levels of integrated and total SIV-DNA were a median of 9980 copies versus 176,500 copies of SIV-DNA per million CD4+ T cells during the chronic phase of infection (*P*=n.s.; data not shown).

![Total and integrated SIV-DNA levels in untreated SHIV-infected RMs. The *Alu-gag* PCR was used to quantify integrated SIV-DNA as compared to total SIV-DNA measured by standard *gag* RT-PCR in 10 RM. PBMC during the acute phase (A,C) and the chronic phase (B,D) of untreated SIV infection. Levels of integrated (E) and total (F) SIV-DNA were also compared between acute and chronic infection. In (C) and (D) lines are drawn at the median](jve-2-219-g002){#jve-2-219-g002}

Frequency of cells harbouring integrated SIV-DNA is similar during the acute and chronic phases of untreated SHIV infection {#jve1-sec-0019}
---------------------------------------------------------------------------------------------------------------------------

We next compared the levels of integrated SIV-DNA as determined by the *Alu-gag* assay in individual animals sampled during the acute and chronic stages of infection. In untreated RMs, there was no significant difference in the level of integrated SIV-DNA between the acute and chronic stages of infection (Figure [2E](#jve-2-219-g002){ref-type="fig"}). By contrast, the level of total SIV-DNA was significantly higher in all RMs during the acute as compared to chronic phase of infection (*P*=0.04; Figure [2F](#jve-2-219-g002){ref-type="fig"}). However, when normalised to CD4+ T cell frequencies, the levels of total SIV-DNA were not significantly different between acute and chronic phases of infection (data not shown).

Integrated SIV-DNA is positively associated with total SIV-DNA {#jve1-sec-0020}
--------------------------------------------------------------

To better understand the relationship between standard virological and immunological assessments in SIV/SHIV-infected RMs and the results of our integrated SIV-DNA assay, we investigated potential correlations between these measures in animals sampled during the acute and chronic stages of infection. Levels of total and integrated SIV-DNA in PBMC were positively correlated during both the acute (r^2^=0.96, *P*\<0.0001) and chronic (r^2^=0.76, *P*=0.01) phases of SIV infection (Figure [3A,B](#jve-2-219-g003){ref-type="fig"}). The same correlations were observed between the estimated levels of total and integrated SIV-DNA in CD4+ T cells during the acute phase (r^2^=0.97, *P*\<0.0001) and chronic phase (r^2^=0.96, *P*\<0.0001) of SIV infection (Figure [3C,D](#jve-2-219-g003){ref-type="fig"}). During the chronic phase of infection, integrated SIV-DNA in PBMC was also negatively correlated with the peripheral CD4 absolute count (r^2^=−0.67, *P*=0.04, data not shown) and showed a trend towards a positive correlation with the plasma SIV-RNA level (r^2^=0.61, *P*=0.07, data not shown).

![Correlations between total and integrated SIV-DNA levels in PBMC and in CD4+ T cells from untreated SHIV-infected RMs. Levels of total and integrated SIV-DNA were not significantly different (A,C) but were positively correlated (B,D). Estimated level of total and integrated SIV-DNA in CD4+ T cells, calculated based on PBMC frequency of infection determined by PCR and the frequency of CD4+ T cells in PBMC determined by flow cytometry, were correlated during both the acute (C) and chronic (D) phases of infection](jve-2-219-g003){#jve-2-219-g003}

Use of the integrated SIV-DNA assay to quantify the frequency of latently infected cells in lymphoid tissues and peripheral blood in ART-treated RMs {#jve1-sec-0021}
----------------------------------------------------------------------------------------------------------------------------------------------------

To further validate our assay, levels of total and integrated SIV-DNA were quantified in cells isolated from multiple lymph nodes and the spleen of five ART-treated RMs with plasma viral load \<60 copies/mL (the limit of detection of our standard assay). These RMs were all started on ART during the chronic phase of SIV infection and had been treated for a median of 404 days (range 183--425 days) at the time of tissue collection (Table [1](#jve1-tbl-0001){ref-type="table"}). Integrated SIV-DNA was readily detected in all lymphoid compartments tested, demonstrating the persistence of integrated proviruses in the setting of undetectable viraemia in this model. The median frequency of cells harbouring integrated SIV-DNA in lymph nodes and spleen was 3160 per million cells. This value is higher than levels of integrated HIV-1 reported in PBMC or resting CD4+ T cells isolated from the peripheral blood of HIV-1-infected ART-suppressed patients, but similar to total HIV-DNA in CD4+ T cells from gut-associated lymphoid tissue [@jve1-bib-0022], reflecting the critical contribution of sites other than peripheral blood to virus persistence. Total SIV-DNA was not significantly different from the frequency of integrated SIV-DNA in ART-treated RMs (Figure [4A](#jve-2-219-g004){ref-type="fig"}), as has been reported for HIV-1-infected patients treated with ART during chronic infection [@jve1-bib-0022].

![Total and integrated SIV-DNA levels in ART-treated SIV-infected RMs. Integrated and total SIV-DNA was measured in lymphoid tissues (A,B) or peripheral CD4+ T cells (C,D) of ART-treated RMs. Levels of integrated and total SIV-DNA were not significantly different (A,C) but were positively correlated (B,C). In (A) and (C) lines are drawn at the median. iLN: ileac lymph node; cLN: colonic lymph node; sLN: superficial lymph node (axillary or inguinal)](jve-2-219-g004){#jve-2-219-g004}

Levels of total and integrated SIV-DNA were also quantified in peripheral CD4+ T cells from an additional eight ART-treated RMs. These RMs were all started on ART during the chronic phase of SIV infection and had been treated for a median of 142.5 days (range 140--144 days) at the time of blood collection (Table [1](#jve1-tbl-0001){ref-type="table"}). Integrated SIV-DNA was detected in the peripheral CD4+ T cells of 8/8 RMs. There was no significant difference in the level of integrated SIV-DNA and total SIV-DNA (median of 2742 and 3786 copies per million CD4+ T cells, respectively, Figure [4C](#jve-2-219-g004){ref-type="fig"}). In both cohorts of ART-treated RMs, total and integrated SIV-DNA levels were positively correlated in the lymphoid tissues (r^2^=0.78, *P*=0.01; Figure [4B](#jve-2-219-g004){ref-type="fig"}) and in the peripheral blood (r^2^=0.76, *P*=0.03; Figure [4D](#jve-2-219-g004){ref-type="fig"}).

Discussion {#jve1-sec-0022}
==========

In this report, we describe the development of an assay quantifying integrated SIV-DNA and its validation using ART-naïve and ART-experienced SIV-infected RM samples. Our assay detects SIV integrated DNA by repetitive sampling *Alu-gag* PCR. One important feature of our assay is the use of a polyclonal integration standard containing proviruses integrated at different distances from the nearest *Alu* element, providing a correction factor for the variable efficiency of the of the *Alu-gag* PCR based on the proximity of the provirus to the *Alu* repeats in each infected cell. Our integration assay requires a total of 840,000 cell equivalents and can detect down to one provirus. The overall assay including DNA extraction, albumin quantification and quantification of total and integrated SIV-DNA levels can be performed in 2 days. As described previously for HIV [@jve1-bib-0017], the limit of detection of the assay can be lowered by increasing the number of genomes per reaction but also by applying a different analysis method, notably by counting the percentage of positive *Alu-gag* signals after using our repetitive sampling *Alu-gag* PCR integration assay and quantifying integrated DNA using Poisson statistics. This type of statistical analysis can be readily applied to the assay described here and will be particularly important for studies of RMs on long-term ART and/or rare reservoirs that contain very low levels of viral DNA.

To validate our assay, levels of integrated and total SIV-DNA in ART-naïve animals were measured in both acute and chronic SIV infection. Using untreated RM PBMC samples, the inter-assay coefficient of variation of the SIV *Alu-gag* integration assay was 0.057; however, this value may differ slightly if samples with lower numbers of integrants are used. As reported in untreated HIV infection, total and integrated SIV-DNA levels in PBMC were positively correlated and the median total SIV-DNA level was significantly higher than the integrated SIV-DNA levels, suggesting the presence of excess unintegrated SIV-DNA forms in ART-naive RMs. Furthermore, in ART-treated RMs, this assay was successfully used to quantify cells harbouring integrated SIV-DNA isolated from peripheral blood, lymph nodes and spleen. During therapy, the median total and integrated SIV-DNA levels did not differ significantly, which presumably reflects the preferential clearance of non-integrated SIV-DNA, as has been reported before [@jve1-bib-0025] and further validates our quantification assays.

We determined that a median of 3160 lymphoid cells per million contain integrated SIV-DNA in RMs on ART for a median of 404 days. Similar levels of integrated SIV-DNA, with a median of 2743 integrated SIV-DNA copies/million CD4+ T cells, were found in peripheral blood in an independent cohort of RMs treated with ART for approximately one-third of this time period (median 142 days) and despite CD4+ T cell enrichment. In line with this result, previous reports in ART-treated RMs and humans showed higher levels of total viral DNA in lymphoid and mucosal tissues as compared to peripheral blood [@jve1-bib-0029]. Our results thus confirm in RMs the critical contribution of sites other than peripheral blood to virus persistence.

A limitation of this work is that samples were not available to compare the results of integrated SIV-DNA to SIV QVOA or the more recently described Tat/rev induced limiting dilution assay (or TILDA). In HIV-1-infected patients both the QVOA and TILDA assays positively correlated with frequency of integrated HIV-DNA in PBMC [@jve1-bib-0022]. Variations of these assays for the SIV system are in use or in development in our and others' laboratories and should be employed as desired depending on the question to be addressed in a particular study.

*In vivo* investigational studies in non-human primates offer a number of important advantages to the HIV cure field. Key amongst these include the ability to control for the timing, dose and route of infection, guaranteed ART adherence, and testing of potentially risky interventions. The integrated SIV-DNA assay described in this report can be added to the armamentarium of evaluations used to measure reservoirs *ex vivo* from SIV-infected, ART-treated RMs.
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